Citation Impact
Citing Papers
Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial
2007 Standout
Dasatinib
2009
Disruption of a Homolog of Trithorax by 11q23 Translocations: Leukemogenic and Transcriptional Implications
1997
Plasma hydroxyurea determined by gas chromatography–mass spectrometry
2008
Hematologic and Cytogenetic Responses to Imatinib Mesylate in Chronic Myelogenous Leukemia
2002 Standout
Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients With Non–Small Cell Lung Cancer
2003 Standout
Clinical Management and Current Research in Isolated Limb Perfusion for Sarcoma and Melanoma
1998
Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia
2001 Standout
The cellular and molecular basis of hyperthermia
2002 Standout
Dasatinib in Imatinib-Resistant Philadelphia Chromosome–Positive Leukemias
2006 Standout
Chronic myelogenous leukemia: A review
1996
Cancer genes and the pathways they control
2004 Standout
Effectiveness and cost-effectiveness of imatinib for first-line treatment of chronic myeloid leukaemia in chronic phase: a systematic review and economic analysis
2004
Conservation, Variability and the Modeling of Active Protein Kinases
2007 StandoutNobel
Tumour heterogeneity and cancer cell plasticity
2013 StandoutNature
Chronic Myelogenous Leukemia
2002
OPTIONS FOR THERAPY IN CHRONIC MYELOID LEUKAEMIA
1995
Sickle-cell disease
2010 Standout
Analysis of anticancer drugs: A review
2011 Standout
Activity of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in the Blast Crisis of Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia with the Philadelphia Chromosome
2001 Standout
Cancer immunotherapy: The interferon-α experience
2002
Natural compounds for cancer treatment and prevention
2009 Standout
Cancer-related fatigue—mechanisms, risk factors, and treatments
2014 Standout
Imatinib Mesylate — A New Oral Targeted Therapy
2002
Herb-Drug Interactions
2005 Standout
2 The histopathology of chronic myeloproliferative diseases
1998
An assessment of the clinicohematological criteria for the accelerated phase of chronic myeloid leukemia
1996
Chronic Myeloid Leukemia
1999
Interferon-γ: an overview of signals, mechanisms and functions
2003 Standout
Chromatin Remodeling and Leukemia: New Therapeutic Paradigms
1999
A safety evaluation of omacetaxine mepesuccinate for the treatment of chronic myeloid leukemia
2016
Approval summary: imatinib mesylate capsules for treatment of adult patients with newly diagnosed philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase.
2003
Treatment of chronic myelogenous leukemia: current status and investigational options [see comments]
1996
Histone Acetyltransferases
2001 Standout
Role of angiogenesis in tumor growth and metastasis
2002 Standout
Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia.
2002
Antiangiogenic Strategies and Agents in Clinical Trials
2000
Treatment of Philadelphia Chromosome-Positive Early Chronic Phase Chronic Myelogenous Leukemia With Daily Doses of Interferon Alpha and Low-Dose Cytarabine
1999
Screening for hyperglycaemia in pregnancy: a rapid update for the National Screening Committee
2010 StandoutNobel
An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: developed for the American Society of Hematology.
1999
Single-Cell Mass Cytometry of Differential Immune and Drug Responses Across a Human Hematopoietic Continuum
2011 StandoutScience
Structural Mechanism for STI-571 Inhibition of Abelson Tyrosine Kinase
2000 StandoutScience
Canarypox Virus-Induced Maturation of Dendritic Cells Is Mediated by Apoptotic Cell Death and Tumor Necrosis Factor Alpha Secretion
2000 StandoutNobel
Plant Secondary Metabolites as Anticancer Agents: Successes in Clinical Trials and Therapeutic Application
2018 Standout
The Importance of Diagnostic Cytogenetics on Outcome in AML: Analysis of 1,612 Patients Entered Into the MRC AML 10 Trial
1998 Standout
The World Health Organization (WHO) classification of the myeloid neoplasms
2002 Standout
Systematic Review: Hydroxyurea for the Treatment of Adults with Sickle Cell Disease
2008
The Tyrosine Kinase Inhibitor CGP57148B Selectively Inhibits the Growth of BCR-ABL–Positive Cells
1997
Biological properties of recombinant alpha-interferons: 40th anniversary of the discovery of interferons.
1998
NATURAL KILLER CELLS IN ANTIVIRAL DEFENSE: Function and Regulation by Innate Cytokines
1999 Standout
Interferon in Oncological Practice: Review of Interferon Biology, Clinical Applications, and Toxicities
2001
Chronic Myelogenous Leukemia: Biology and Therapy
1999
Works of DK Hossfeld being referenced
Randomized comparison of busulfan and hydroxyurea in chronic myelogenous leukemia: prolongation of survival by hydroxyurea. The German CML Study Group
1993
Randomized comparison of busulfan and hydroxyurea in chronic myelogenous leukemia: prolongation of survival by hydroxyurea. The German CML Study Group
1993
Pharmacokinetics of Doxorubicin in the Heparinized Perfusate during Isolated Hyperthermic Limb Perfusion
1993
Pre-pre-B acute lymphoblastic leukemia: high frequency of alternatively spliced ALL1-AF4 transcripts and absence of minimal residual disease during complete remission
1994
Randomized comparison of interferon-alpha with busulfan and hydroxyurea in chronic myelogenous leukemia. The German CML Study Group [see comments]
1994